Does IMVT pay a dividend and is it safe?

Immunovant Inc. (IMVT) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / IMVT / dividends

KOD (54) CGON (42) SRRK (41) CRSP (35) ⌘ Pro Terminal →

Immunovant Inc. (IMVT) Dividend Safety Gauge & 10-Year DRIP Compounder

$28.41 -2.60% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $28.22

Immunovant Inc. (IMVT) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $5.87B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on IMVT Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is IMVT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Immunovant Inc. (NASDAQ: IMVT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $28.41 (-2.60% 1D, market cap $5.87B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, IMVT ranks #526 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does IMVT compare to KOD and CGON in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IMVT carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, KOD (Kodiak Sciences Inc) holds a D+ grade (54/100 RQD, P/E N/A, ROIC -35.0%, cap $6.14B) and CGON (CG Oncology Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -20.8%, cap $5.49B). Among the 5-stock peer group, IMVT leads on earnings multiple (N/A) while CGON leads on capital efficiency (-20.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for IMVT?

▼

Per IMVT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0001764013), Immunovant Inc. generated $1.67B in revenue (+22.2% YoY), -$505.6M in net income, and -$407.3M in free cash flow against $1.05B in total assets and $29.8M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $28.22 (-0.66%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

2-of-3 Quant Analysts Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IMVT)Realized 20D OHLCV Swing Band: ±7.2%

Deterministic 5-Pillar Attribution (37/100 Composite)

🔍 WHY IMVT SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (38% of score)

Altman Z-Score 26.00 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 0% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$27.51+5.8% Next Q

Q2 (-2Q)

Grade E$29.10+1.9% Next Q

Q3 (-1Q)

Grade E$29.64-4.1% Next Q

Current

Grade D-$28.41-8.1% Hist 90D α

Trajectory: E (29) → D- (37)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a IMVT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While IMVT currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($33.39) and Max Pain ($29.83) forces dealer call-delta covering toward $47.69.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $IMVT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “IMVT Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”

YES 37%NO 63%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,908

Est. Year-10 Shareholder Yield: $107/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.2K

Yr 2

$11.9K

Yr 3

$12.6K

Yr 4

$13.4K

Yr 5

$14.2K

Yr 6

$15.0K

Yr 7

$15.9K

Yr 8

$16.9K

Yr 9

$17.9K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IMVT)

✓Walkthrough of IMVT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

IMVT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +2.05%📐 HORIZONTAL RANGE

2026-11-04O $29.17H $29.17L $28.41C $28.41VOL 1.27M

RES: $53.53SUP: $23.95SMA50: $33.39SMA200: $32.10

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IMVT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IMVT Butterfly Map → + Track IMVT →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

27.7%/yr Implied 5Y Growth

vs. +22.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on IMVT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IMVT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for IMVT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IMVT)

Health Care Rank #526 of 1015 ⚔️ KOD vs IMVT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IMVT vs. KOD, CGON, SRRK, CRSP)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Immunovant Inc. (IMVT) ranks #526 by composite RQD confidence (37/100, grade D-) and #145 by equity capitalization ($5.87B). Within this direct 5-issuer industry benchmark cohort, IMVT leads on earnings valuation at N/A trailing P/E, while CGON leads on capital efficiency and profitability with -20.8% ROIC and — gross margin. KOD currently holds the highest overall quantitative score in the immediate peer group at 54/100 (D+) compared with IMVT at 37/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
IMVT ACTIVE Immunovant Inc.	D-	37/100	—	—	-35.0%	-2.60%	$5.87B	Benchmark Subject
KOD Kodiak Sciences Inc	D+	54/100	—	—	-35.0%	-1.57%	$6.14B	/kod-vs-imvt →
CGON CG Oncology Inc.	D-	42/100	—	—	-20.8%	-4.20%	$5.49B	/cgon-vs-imvt →
SRRK Scholar Rock Holding Corporation	D-	41/100	—	—	-35.0%	-2.25%	$5.23B	/srrk-vs-imvt →
CRSP CRISPR Therapeutics AG	D-	35/100	—	—	-30.6%	-2.78%	$4.83B	/crsp-vs-imvt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-03-31 • CIK 0001764013 ↗

In its most recent audited fiscal period (FY2025, filed 2026-03-31), Immunovant Inc. (IMVT) reported GAAP revenue of $1.67B (+22.2% vs. FY2024 revenue of $1.37B , and +95.0% cumulative change since FY2023) , GAAP net income of -$505.6M, operating cash flow of -$407.3M, and free cash flow of -$407.3M (-8.1% YoY). On the balance sheet, IMVT closed FY2025 with $1.05B in total assets against $29.8M in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2026-03-31	$1.67B	-$505.6M	-$407.3M	-$407.3M	$1.05B	$29.8M
FY2024 (FY)	2025-03-31	$1.37B	-$413.8M	-$375.9M	-$376.6M	$420.9M	$30.7M
FY2023 (FY)	2024-03-31	$856.8M	-$259.3M	-$214.2M	-$214.2M	$3.37B	$787.9M

3. IMVT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IMVT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does IMVT compare to KOD and CGON in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for IMVT?

Where is IMVT trading relative to its 50-day, 200-day, and 52-week technical levels?

IMVT last traded at $28.41 (-2.60% on volume of 1,268,062 shares), positioning the stock -14.91% below its 50-day simple moving average ($33.39) and -11.50% below its 200-day simple moving average ($32.10). Across its 52-week range of $21.43 to $45.42, IMVT sits at the 29.1% percentile with a 14-day RSI of 36.4 (NEUTRAL RANGE) and an implied next-earnings move of ±7.2% ($26.36 to $30.46).

Direct Sub-Reports: IMVT RQD Cockpit IMVT 12M Forecast IMVT Earnings & Move IMVT Dividends & DRIP IMVT Insiders & 13F IMVT Whale Options IMVT Profit Sankey IMVT News & Why

ROARABLE RATING BRIEF • RQD 37/100 (D-) ✓ SEC XBRL & RQD VERIFIED

IMVT — Immunovant Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2026-03-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Immunovant Inc. (IMVT) earns a live Roarable RQD composite score of 37/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $28.41 (-2.60% 1D, market capitalization $5.87B).

Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -36.0%, and free cash flow yield of -6.65%.
Whale 13F & Options Flow (5/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (5/20) + Forensic Balance Sheet (14/20): Incorporates a 0.98x equity beta, Altman Z-Score of 26.00, Piotroski F-Score of 5/9, and Debt/Equity of 0.03x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Immunovant Inc. (IMVT) is a NASDAQ-listed company in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry,. Reported revenue is — in each of FY 2023, FY 2024, and FY 2025, so the source data shows no revenue generation across the reported periods.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2026-03-31), Immunovant Inc. (IMVT) reported $1.67B in annual revenue (up from $1.37B in FY2024, +22.2% YoY) and -$505.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($856.8M revenue, -$259.3M net income) through FY2025, IMVT scaled operating cash flow to -$407.3M and free cash flow to -$407.3M, backed by $1.05B in total assets against $29.8M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D- • RQD 37/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -6.65% and institutional whale pillar of 5/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $21.43 – $45.42 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -36.0% operating margins and a 0.98x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore — The only sector context provided is Health Care / Biotechnology: Biological Products, and beta is 0.98.

Key Question #1: Can IMVT sustain or expand its -36.0% operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $1.67B and free cash flow of -$407.3M, how will capital allocation balance growth reinvestment against $29.8M in total debt?
Key Question #3: How sensitive is IMVT's 36.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.98x)?

IMVT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Immunovant Inc. (IMVT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to IMVT Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 1d ago

Immunovant (IMVT) Stock Looks Stretched On Book Value Alone

Yahoo Finance report covering Immunovant Inc. (IMVT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Seeking Alpha • 1d ago

Immunovant: Batoclimab 2.0 Bull Case Flawed By Mixed Data, Competitive Threats

Seeking Alpha report covering Immunovant Inc. (IMVT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 2d ago

Is Immunovant (IMVT) Undervalued On Its CLE Trial Setback?

Simply Wall St report covering Immunovant Inc. (IMVT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 2d ago

Immunovant, Inc. Estimates – NASDAQ:IMVT

TradingView report covering Immunovant Inc. (IMVT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com • 2d ago

Immunovant CEO Eric Venker sells $119,589 in shares

Investing.com report covering Immunovant Inc. (IMVT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 2d ago

Immunovant Q1 2027 Earnings Call: Complete Transcript

Benzinga report covering Immunovant Inc. (IMVT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Traders Daily • 2d ago

How Immunovant Inc. (IMVT) Affects Rotational Strategy Timing

Stock Traders Daily report covering Immunovant Inc. (IMVT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 2d ago

IMVT, ROIV Stocks Slide As Argenx Sjögren’s Trial Failure Hits Drug Class

Yahoo Finance report covering Immunovant Inc. (IMVT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

IMVT Bull vs. Bear Conversation Board — What's Your Call at $28.41?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON IMVT 🐻 33% BEARISH CONVICTION

BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $35.59 (+22.0%)

📌 Pinned Debate

Forensic balance sheet is the strongest pillar, with Debt/Equity of 0.03 and cash of $994.5M in FY 2025 against debt of $29.8M.

Picked up a starter position in IMVT in my $100K Virtual Cash book at $29.17. Forensic balance sheet is the strongest pillar, with Debt/Equity of 0.03 and cash of $994.5M in FY 2025 against debt of $29.8M.. Trading inside a $21.43–$45.42 52-week range with -6.65% FCF yield gives solid downside support if Biotechnology: Biological Products (No Diagnostic Substances) multiples expand this quarter.

EarningsSniper 🐂 BULL

Both sides have a point here — IMVT's 14/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $22.75 (-22.0%)

Spot @ $29.17

The company reports $0.0M revenue with operating losses of -$596.6M and FCF of -$407.3M in FY 2025, and ROIC is -35%.

Careful chasing IMVT at $29.17. The company reports $0.0M revenue with operating losses of -$596.6M and FCF of -$407.3M in FY 2025, and ROIC is -35%.. Gross margin is 0.0%, but operating margin is -36.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $22.75 on multiple compression.